title: Etanercept and urticaria in patients with juvenile idiopathic arthritis.
abstract: Etanercept, a tumor necrosis factor receptor p75 Fc fusion protein (TNFR:Fc; Enbrel), has preliminarily been shown to be effective in the management of methotrexate-resistant polyarticular juvenile idiopathic arthritis (JIA). Reported side-effects have been minor, for example injection site reactions and upper respiratory tract infections, not necessitating discontinuation of the medication (1, 2). We report on 2 patients who developed an urticaria-like rash with prurigo appearing bilaterally on the extensor surfaces of the elbows subsequent to etanercept injections.
authors.affiliation: Rheumatism Foundation Hospital, Heinola, Finland.
authors.forename: E
authors.initials: E
authors.lastname: Skyttä
authors.forename: H
authors.initials: H
authors.lastname: Pohjankoski
authors.forename: A
authors.initials: A
authors.lastname: Savolainen
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002675:Child, Preschool; D004550:Elbow; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D018124:Receptors, Tumor Necrosis Factor; D014581:Urticaria / Q000139:chemically induced*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept